New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

  • Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1
     
  • Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs 6.87) in a 52-week study2
     
  • Approximately 100,000 people in the United States, most of whom are of African descent, have sickle cell disease3
     
  • Approval comes approximately two months ahead of FDA’s priority review action …
/by

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

  • If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1])
     
  • CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline[2]
     
  • Up to 80% of patients with relapsing remitting …
/by